Last update: Dec. 8, 2017
Minimal risk for breastfeeding and infant.
Antibacterial carbapenem beta-lactam with indications similar to imipenem.
Intravenous administration a daily dose.
It is excreted in breast milk in a clinically insignificant amount (Merck 2012).
Authorized pediatric use in infants from 3 months of age.
Its low oral bioavailability would make it difficult for it to pass to the infant’s plasma ingesting breast milk, except in preterm infants and in the immediate neonatal period when there may be increased intestinal permeability.
The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to altered intestinal flora (Benyamini 2005, Ito 1993, Kafetzis 1981).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM